Original Article

Host-parasite Responses Outcome Regulate the Expression of Antimicrobial Peptide Genes in the Skin of BALB/c and C57BL/6 Murine Strains Following Leishmania major MRHO/IR/75/ER Infection


Background: Different background of immunity responses determine resistance or susceptibility of certain mouse strains to Leishmania major infection. Some have been well known previously. Antimicrobial peptides (AMPs) such as cathelicidins and defensins are unique fragments of innate immunity system with well-known effects against the invasion pathogens. Despite their outstanding roles and being of extensive cases of cutaneous leishmaniasis (CL) caused by L. major, they have been less studied in Leishmania fields. The aim of present study was to determine whether these components play a role in the protection of skin against Leishmania infections.

Methods: The animal model of Leishmania infection was established by the subcutaneous inoculation of 5×106(parasites/ml) from the stationary phase of L. major promastigotes to BALB/c and C57BL/6 mice from January 2016 to August 2016 in Kerman Province, southeast of Iran. After 1, 3 and 7 d of post-infection (PI), the samples needed for detecting of the mRNA levels of mouse beta-defensin (mBD)-1, mBD2, mBD3, mBD4, mBD6, cathlin-related antimicrobial peptide (CRAMP), interleukin (IL)-10, IL-12 and parasite load were taken under standard methods.

Results: The findings related to cytokines profiles in BALB/c (­IL-10, ¯IL-12) and C57BL/6 mouse strains (¯IL-10, ­IL-12) demonstrated that immunity system has been accurately activated during CL caused by L. Major parasites. We also observed a significant up-regulation of all aforementioned AMPs genes in BALB/c mice at selected times compared to another strain.

Conclusion: CL occurred in BALB/c mice in spite of the fact that the expression of AMPs was higher than the other strain. AMPs genes are well expressed to provide defense against the parasites that have increased and escaped from immunity system but cannot create an absolute protection.

1. Alvar J, Vélez ID, Bern C et al. Leishmaniasis worldwide and global estimates of its incidence. PLoS One. 2012; 7(5):e35671.
2. Herwaldt BL. Leishmaniasis. Lancet. 1999; 354(9185):1191-9.
3. Akhoundi M, Kuhls K, Cannet A et al. A Historical Overview of the Classification, Evolution, and Dispersion of Leishmania Parasites and Sandflies. PLoS Negl Trop Dis. 2016; 10(3):e0004349.
4. Dostálová A, Volf P. Leishmania development in sand flies: parasite-vector interactions overview. Parasit Vectors. 2012; 5:276.
5. Postigo JA. Leishmaniasis in the world health organization eastern mediterranean region. Int J Antimicrob Agents. 2010; 36 Suppl 1:S62-5.
6. Holakouie-Naieni K, Mostafavi E, Boloorani AD et al. Spatial modeling of cutaneous leishmaniasis in Iran from 1983 to 2013. Acta Trop. 2017; 165:90-95.
7. Krishnan L, Guilbert LJ, Wegmann TG et al. T helper 1 response against Leishmania major in pregnant C57BL/6 mice increases implantation failure and fetal resorptions. Correlation with increased IFN-gamma and TNF and reduced IL-10 production by placental cells. J Immunol. 1996; 156(2):653-62.
8. Okwor I, Uzonna JE. Pathways leading to interleukin-12 production and protective immunity in cutaneous leishmaniasis. Cell Immunol. 2016; 309:32-36.
9. Kane MM1, Mosser DM. The role of IL-10 in promoting disease progression in leishmaniasis. J Immunol. 2001; 166(2):1141-7.
10. Lazarski CA, Ford J, Katzman SD et al. IL-4 attenuates Th1-associated chemokine expression and Th1 trafficking to inflamed tissues and limits pathogen clearance. PLoS One. 2013; 8(8):e71949.
11. Dubos RJ. Studies on a bactericidal agent extracted from a soil bacillus: I. Preparation of the agent. Its activity in vitro. J Exp Med. 1939; 70(1):1-10.
12. Zhao X, Wu H, Lu H et al. LAMP: a database linking antimicrobial peptides. PLoS One. 2013; 8(6):e66557.
13. Zasloff M. Antimicrobial peptides of multicellular organisms. Nature. 2002; 415(6870):389-95.
14. Yeaman MR, Yount NY. Mechanisms of antimicrobial peptide action and resistance. Pharmacol Rev. 2003; 55(1):27-55.
15. Bals R, Wilson JM. Cathelicidins-a family of multifunctional antimicrobial peptides. Cell Mol Life Sci. 2003; 60(4):711-20.
16. Ganz T. Defensins: antimicrobial peptides of innate immunity. Nat Rev Immunol. 2003; 3(9):710-20.
17. Fellermann K, Wehkamp J, Stange EF. Antimicrobial peptides in the skin. N Engl J Med. 2003; 348(4): 361-363.
18. Hu SG, Zou M, Yao GX et al. Androgenic regulation of beta-defensins in the mouse epididymis. Reprod Biol Endocrinol. 2014; 12;76.
19. Deng YY, Shamoon M, He Y et al. Cathelicidin-related antimicrobial peptide modulates the severity of acute pancreatitis in mice. Mol Med Rep. 2016; 13(5):3881-5.
20. Hemshekhar M, Anaparti V, Mookherjee N. Functions of Cationic Host Defense Peptides in Immunity. Pharmaceuticals (Basel). 2016; 9(3).
21. Ray A, Dittel BN. Isolation of mouse peritoneal cavity cells. J Vis Exp. 2010; (35).
22. Livak KJ, Schmittgen TD. Analysis of relative gene expression data using real-time quantitative PCR and the 2− ΔΔCT method. Methods. 2001; 25(4):402-8.
23. Gomes AH, Ferreira IM, Lima ML et al. PCR identification of Leishmania in diagnosis and control of canine leishmaniasis. Vet Parasitol. 2007; 144(3-4):234-41.
24. Almani PG, Sharifi I, Kazemi B et al. The role of GlcNAc-PI-de-N-acetylase gene by gene knockout through homologous recombination and its consequences on survival, growth and infectivity of Leishmania major in in vitro and in vivo conditions. Acta Trop. 2016; 154:63-72.
25. Stefaniak J, Paul M, Kacprzak E et al. (Visceral leishmaniasis). Przegl Epidemiol. 2003; 57(2):341-8. [Article in Polish]
26. Valesky EM, Thaçi D, Meissner M et al. Cutaneous leishmaniasis: clinical report of two cases and review of the recent literature. J Dtsch Dermatol Ges. 2007; 5(9):770-2. [Article in English, German]
27. Okwor I, Uzonna J. Social and Economic Burden of Human Leishmaniasis. Am J Trop Med Hyg. 2016; 94(3):489-93.
28. Oliaee RT, Sharifi I, Afgar A et al. Unresponsiveness to meglumine antimoniate in anthroponotic cutaneous leishmaniasis field isolates: analysis of resistance biomarkers by gene expression profiling. Trop Med Int Health. 2018; 23(6):622-633.
29. Sacks D, Noben-Trauth N.. The immunology of susceptibility and resistance to Leishmania major in mice. Nat Rev Immunol. 2002; 2(11):845-58.
30. Park AY, Hondowicz BD, Scott P. IL-12 is required to maintain a Th1 response during Leishmania major infection. J Immunol. 2000; 165(2):896-902.
31. Alexander J, Bryson K. T helper (h)1/Th2 and Leishmania: paradox rather than paradigm. Immunol Lett. 2005; 99(1):17-23.
32. Ronet C, Hauyon-La Torre Y, Revaz-Breton M et al. Regulatory B cells shape the development of Th2 immune responses in BALB/c mice infected with Leishmania major through IL-10 production. J Immunol. 2010; 184(2):886-94.
33. Beato M. Gene regulation by steroid hormones. Cell. 1989; 56(3): 335-344.
34. Prina E, Roux E, Mattei D et al. Leishmania DNA is rapidly degraded following parasite death: an analysis by microscopy and real-time PCR. Microbes Infect. 2007; 9(11):1307-15.
IssueVol 13 No 4 (2018) QRcode
SectionOriginal Article(s)
Antimicrobial peptides Cathelicidin Cathelin-related antimicrobial peptide Cytokine Defensin Leishmania major Mouse β-defensin

Rights and permissions
Creative Commons License This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
How to Cite
DANESHVAR H, TAVAKOLI KARESHK A, SHARIFI I, KEYHANI A, ASADI A, TAVAKOLI OLIAEE R. Host-parasite Responses Outcome Regulate the Expression of Antimicrobial Peptide Genes in the Skin of BALB/c and C57BL/6 Murine Strains Following Leishmania major MRHO/IR/75/ER Infection. Iran J Parasitol. 2018;13(4):515-523.